<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Recipients of hematopoietic stem cell transplantation (HSCT) frequently have <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> resulting from <z:hpo ids='HP_0011010'>chronic</z:hpo> transfusion therapy for <z:hpo ids='HP_0001903'>anemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In some cases, for example, in patients with <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> and <z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e>, this can be further exacerbated by increased absorption of iron from the gut as a result of <z:hpo ids='HP_0010972'>ineffective erythropoiesis</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Accumulating evidence has established the negative impact of elevated pretransplantation serum ferritin, a surrogate marker of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e>, on overall survival and nonrelapse mortality after HSCT </plain></SENT>
<SENT sid="3" pm="."><plain>Complications of HSCT associated with <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> include increased <z:mp ids='MP_0001794'>bacterial</z:mp> and <z:e sem="disease" ids="C0026946" disease_type="Disease or Syndrome" abbrv="">fungal infections</z:e> as well as <z:e sem="disease" ids="C0019156" disease_type="Disease or Syndrome" abbrv="">sinusoidal obstruction syndrome</z:e> and possibly other regimen-related toxicities </plain></SENT>
<SENT sid="4" pm="."><plain>Based on current evidence, particular attention should be paid to prevention and management of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in allogeneic HSCT candidates, especially in patients with <z:e sem="disease" ids="C0039730" disease_type="Disease or Syndrome" abbrv="">thalassemia</z:e> and <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>The pathophysiology of <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> in the HSCT patient and optimum strategies to deal with <z:e sem="disease" ids="C0282193" disease_type="Disease or Syndrome" abbrv="">iron overload</z:e> during and after HSCT require further study </plain></SENT>
</text></document>